Fred R. Hirsch, MD, PhD Professor of Medicine and Pathology, Associate Director for International Programs, University of Colorado Cancer Center, discusses the role of next-generation EGFR inhibitors for patients with non-small cell lung cancer.

Many patients develop resistance to first-generation EGFR inhibitors through the acquisition of a 

 mutation. However, the next-generation EGFR TKIs seem to overcome this specific mutation, Hirsch says. This gives physicians new hope to treat patients after they have become resistant to first-generation EGFR TKIs.

In addition to the continued efficacy in resistant patients, the new generation of EGFR TKIs are also better tolerated compared to the first generation of EGFR TKIs. Further research is needed to determine if these next-generation EGFR inhibitors can be combined with other agents in order get closer to a cure, Hirsch states.

View more from the 15th Annual International Lung Cancer Congress

Conference

® Conference page includes a listing of all conferences covered by 

, including the ASCO, ESMO, SITC, EHA, ASH, and SABCS annual meetings, as well as the Chemotherapy Foundation Symposium and Miami Breast Cancer Conference, among many others. Conference coverage incorporates articles and interviews in written and video format.


Lung Cancer

JAN-22-OSD1275 - /clinical/lung-cancer

The OncLive Lung Cancer condition center page is a comprehensive resource for clinical news and expert insights on non–small cell lung cancer, small cell lung cancer, mesothelioma, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in lung cancer.

Precision Medicine in Oncology®

The OncLive Precision Medicine in Oncology® condition center page is a comprehensive resource for clinical news and expert insights on precision-focused approaches in patients with cancer, with gene-targeted tyrosine kinase inhibitors and antibody-drug conjugates, checkpoint inhibitors, tumor-infiltrating lymphocyte therapy, and other tailored treatments. This page features news articles, interviews in written and video format, and podcasts that focus on updates and ongoing research with personalized therapies across solid and hematologic tumors.

International Lung Cancer Congress

Fred R. Hirsch, MD, PhD Professor of Medicine and Pathology, Associate Director for International Programs, University of Colorado Cancer Center, discusses the role of next-generation EGFR inhibitors.

Dr. Hirsch Discusses the Role of Next-Generation EGFR Inhibitors